from southern Africa. We report an outbreak of ATBF with an attack rate of 100% among 12 Dutch travelers to Swaziland.
The 12 travelers (9 male and 3 female) visited Mkhaya Game Reserve in Swaziland in May 2003 for several days. Upon retuning to the Netherlands, they consulted our clinic for assessment for fever, malaise, and skin eruptions. Epidemiologic and clinical data were obtained after the patients provided informed consent. All symptomatic patients were treated before serum samples were collected.
Acute-phase and convalescencephase serum samples were obtained from 8 patients at 3 and 9 weeks, respectively, after symptoms were reported. Only convalescent-phase serum samples were obtained from the other 4 patients. Serologic assays were conducted for screening and confirmation in Rotterdam, the Netherlands (Department of Virology, Erasmus University Hospital) and Marseille, France (Unité des Rickettsies, Faculté de Médecine, Université de la Mediterranée), respectively.
In Rotterdam, immunofluorescence assays for immunoglobulin G (IgG) and IgM against R. conorii, R. typhi, and R. rickettsii were performed with multiwell slides on which antigens were fixed (Panbio Inc., Columbia, MD, USA). Serum samples with fluorescent rickettsiae at dilutions >1:32 were considered positive.
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In Marseille, a microimmunofluorescence assay for IgG and IgM against R. africae, other members of the spotted fever group, and R. typhi of the typhus biogroup was used. Western blotting for R. africae and R. conorii was performed with reactive serum samples and repeated after cross-adsorption that removed only antibodies to R. conorii (5) . Serologic evidence for infection with R. africae was defined as 1) seroconversion; 2) IgG titers >64, IgM titers >32, or both, with IgG and IgM titers >2 dilutions higher than any of the other tested spotted fever group rickettsial antigens; 3) a Western blot profile that showed R. africae-specific antibodies; and 4) cross-adsorption assays that showed homologous antibodies against R. africae (1).
All 12 travelers had a diagnosis of ATBF. Epidemiologic, clinical, and serologic results are shown in the Table. Two patients had a history of a tickbite. Lymphadenopathy in the groin was the only clinical sign observed in 2 other patients. For all 10 patients with symptoms, the symptoms abated within a few days after treatment with doxycycline, 100 mg orally twice a day (5 
Assays in both locations showed serologic reactivity against R. conorii and R. rickettsiae. Specific antibodies against R. africae were detected by Western blot in 8 patients (Table) . All 12 travelers were infected with R. africae. In 3 other patients, immunofluorescence assays demonstrated seroconversion for specific antibodies. One patient with no clinical symptoms had low IgG (32) and IgM (16) titers against rickettsiae by immunofluorescence and IgG by Western blot.
Tick vectors of R. africae attack humans throughout the year. The proportion of patients having multiple eschars, which indicate the aggressive behavior of the tick, varies from 21% (6) to 54% (2). The 100% attack rate observed in this study emphasizes the risk for ATBF in sub-Saharan travelers. In our study group, only 2 persons had multiple eschars, but serologic analysis showed that all patients were infected with R. africae. Most cases of ATBF have a benign and self-limiting course with fever, headache, myalgia, and a skin rash. However, patients who are not treated show prolonged fever, reactive arthritis, and subacute neuropathy (7) .
The long-term sequelae of ATBF remain to be established. Early treatment would not likely have prevented these complications. Jensenius et al. reported that travel from November through April was a risk factor for ATBF (1) To the Editor: Acinetobacter species are ubiquitous in the environment. In recent years, some species, particularly A. baumannii, have emerged as important nosocomial pathogens because of their persistence in the hospital environment and broad antimicrobial drug resistance patterns (1,2). They are often associated with clinical illness including bacteremia, pneumonia, meningitis, peritonitis, endocarditis, and infections of the urinary tract and skin (3). These conditions are more frequently found in immunocompromised patients, in those admitted to intensive care units, or in those who have intravenous catheters, and those who are receiving mechanical ventilation (4, 5) .
The role of A. baumannii in nosocomial infections has been documented (2), but the clinical effect of other Acinetobacter species has not been investigated. A. lwoffii (formerly A. calcoaceticus var. lwoffii) is a commensal organism of human skin, oropharynx, and perineum that shows tropism for urinary tract mucosa (6) . Few cases of A. lwoffii bacteremia have been reported (3, (5) (6) (7) . We report a 4-year (2002-2005) retrospective study of 10 patients with A. lwoffii bacteremia admitted to a 600-bed teaching hospital in central Italy.
All 10 patients were immunocompromised; 8 had used an intravascular catheter (peripheral or central) and 2 had used a urinary catheter. Blood cultures of the patients were analyzed with the BacT/ALERT 3D system (bioMérieux, Marcy l'Etoile, France). Isolates were identified as A. lwoffii by using the Vitek 2 system and the API 20NE system (both from bioMérieux). A. lwoffii isolates were genotyped by pulsed-field gel electrophoresis (PFGE) to determine their epidemiologic relatedness. Chromosomal DNA was digested with SmaI (9) and analyzed with a CHEF DR II apparatus (Bio-Rad Laboratories, Hercules, CA, USA). PFGE patterns were classified as identical, similar (differed by 1-3 bands), or distinct (differed by >4 bands) (10).
Among the 10 A. lwoffii isolates, 6 were susceptible to all drugs except cephalosporins (cefepime, cefotaxime, ceftazidime, and ceftriaxone) and aztreonam. The other 4 isolates were MDR: 3 were susceptible only to imipenem (MICs 1-4 µg/mL), meropenem (MICs 1-2 µg/mL), and amikacin (MICs 2-4 µg/mL). The fourth MDR strain was susceptible to imipenem (MIC 2 µg/mL), meropenem (MIC 2 µg/mL), amikacin (MIC 4 µg/mL), and ciprofloxacin (MIC 1 µg/mL). Seven antimicrobial drug resistance profiles were detected (Table) .
Macrorestriction analysis of the A. lwoffii isolates identified 8 distinct PFGE types. Two MDR strains (strains 2 and 3 in the Table) , which
